At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 540 enrolled
Drug / intervention
HCQdrug
Likely dose
HCQ 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial
In Brief
A Phase 3 clinical trial evaluating HCQ for Covid19 and Progression. Completed, enrolled 540 participants across 1 site.
Detailed Summary
Brief Summary: Purpose of this study is to evaluate efficacy of hydroxychloroquine (HCQ) in reducing progression of Corona Virus Disease 2019 (COVID - 19) and achieving viral clearance. Condition or disease :I COVID-19 ntervention/treatment :Drug: Hydroxychloroquine Sulfate Phase: Phase III
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, Progression
CountriesPakistan
CollaboratorsPak Emirates Military Hospital
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartApr 2020
Primary CompletionMay 2020
First PostedJul 2020
TodayJul 2026
First PostedJul 30, 2020
Enrollment StartApr 10, 2020
Primary CompletionMay 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.9 years ago
Interventions
HCQdrug
Tab HCQ 400mg 12 hourly day 0 followed by tab HCQ 200mg 12 hrly for next 5 days